Effect of the histone deacetylase inhibitor trichostatin A in human peripheral blood lymphocytes as a function of donor age

Annals of the New York Academy of Sciences

Volumn 1119, Issue 1, 2007, Pages 64-71

  Sourlingas, T G ^a   Kypreou, K P ^b   Topakas, G N ^c   Karchilaki, I N ^c   Stavropoulos Giokas, C ^c   Sekeri Pataryas, K E ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

Aging; Apoptosis; Histone deacetylase inhibitors; Human peripheral blood lymphocytes; Trichostatin A

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ACETYLATION; ADULT; AGED; AGING; APOPTOSIS; CANCER CELL; CELL CULTURE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG EFFECT; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOCYTE; PERIPHERAL LYMPHOCYTE;

EID: 36549062991     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1404.014     Document Type: Conference Paper

References (16)

1. KOUZARIDES, T. 1999. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Gen. Dev. 9: 40-48.
2. BOLDEN, J.E., M.J. PEARL & R.W. JOHNSTONE. 2006. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Disc. 5: 760-784.
3. MINUCCI, S. & P.G. PELICCI. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Drug Disc. 6: 38-51.
4. DE RUIJTER, A.J.M., A. VAN GENNIP, H.N. CARON, et al. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370: 737-749.
5. BI, G. & G. JIANG. 2006. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell. Mol. Immunol. 3: 285-290.
6. MELNICK, A. & J.D. LICHT. 2002. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9: 322-332.
7. DRUMMOND, D.C., C.O. NOBLE, D.B. KIRPOTIN, et al. 2005. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45: 495-528.
8. SOURLINGAS, T.G., D.S. TSAPALI, A.D. KALDIS & K.E. SEKERI-PATARYAS. 2001. Histone deacetylase inhibitors induce apoptosis in peripheral blood lymphocytes along with histone H4 acetylation and the expression of the linker histone variant, H10. Eur. J. Cell Biol. 80: 726-732.
9. ? lymphocytes during ageing. Exp. Gerontol. 39: 539-544.
10. SZMIT, E., P. TRZONKOWSKI, J. MYSLIWSKA, et al. 2002. Ex vivo apoptotic potential of peripheral blood mononuclear cells of the elderly human subject. Cell Biol. Intern. 26: 517-527.
11. DONNINI, A., F. RE, M. BOLLETTINI, et al. 2005. Age-related susceptibility of naive and memory CD4 T cells to apoptosis induced by IL-2 deprivation or PHA addition. Biogerontology 6: 193-204.
12. GUPTA, S. 2005. Molecular mechanisms of apoptosis in the cells of the immune system in human ageing. Immun. Rev. 105: 114-129.
13. SOURLINGAS, T.G., K.P. KYPREOU & K.E. SEKERI-PATARYAS. 2002. The effect of the histone deacetylase inhibitor, trichostatin A, on total histone synthesis, H1(0) synthesis and histone H4 acetylation in peripheral blood lymphocytes increases as a function of increasing age: a model study. Exp. Gerontol. 37: 341-348.
14. KYPREOU, K.P., T.G. SOURLINGAS & K.E. SEKERI-PATARYAS. 2004. Age-dependent response of lymphocytes in the induction of the linker histone variant, H1 degrees and histone H4 acetylation after treatment with the histone deacetylase inhibitor, trichostatin A. Exp. Gerontol. 39: 469-479.
15. LI, G.C., X. ZHANG, T.J. PAN, et al. 2006. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int. J. Urol. 13: 581-586.
16. MOREIRA, J.M.A., P. SCHEIPERS & P. SORENSEN. 2003. The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer 3: 30.